BioNexus Gene Lab Corp（BGLC）價格預測BGLCBioNexus Gene Lab Corp

Alphio's BGLC stock price prediction model matches the current BioNexus Gene Lab Corp tape against historical breakout patterns, then publishes 1-day and 1-week targets first. The 1-day print is $0.90 (+0.84%). The 1-week path is $0.88 (-0.97%). Longer windows use the same pattern set plus seasonality; the 1-month and multi-year forecasts sit behind unlock because they include precise min / avg / max bands.

BioNexus Gene Lab Corp (BGLC) is not a good buy right now due to its extremely low RSI of 17.871, indicating it is oversold, and a staggering year-to-date change of -78.93%. The stock has also seen a 5-day decline of -9.54%, suggesting continued downward momentum. While there was a recent product launch, the overall financial performance shows significant losses, with a net income loss of -286,451 USD in Q2 2026 and a gross margin of only 17.05%. The main risk is its current price of 0.83, which is close to its 52-week low of 0.82, indicating limited downside protection. Overall, the combination of poor financials, negative momentum, and lack of analyst support leads to a recommendation to sell.

BioNexus Gene Lab Corp (BGLC) last closed at $0.8923, gaining +7.51%. These facts feed the 1-day and 1-week BGLC price prediction above.